Search our Database of Scientific Publications and Authors

I’m looking for a

    4186 results match your criteria Macular Edema Diabetic

    1 OF 84

    Subthreshold micropulse laser reduces anti-VEGF injection burden in patients with diabetic macular edema.
    Eur J Ophthalmol 2017 Jul 20. Epub 2017 Jul 20.
    Department of Ophthalmology and Vision Science, University of California Davis Eye Center, Sacramento, California - USA.
    Purpose: To evaluate the efficacy of micropulse laser in the early treatment of diabetic macular edema (DME) and its associated burden of anti-vascular endothelial growth factor (VEGF) injections.

    Methods: This retrospective comparative study compared a group of 19 eyes with DME treated with micropulse laser to a matched control group of 19 eyes with DME treated with ranibizumab injections without micropulse laser. Recorded parameters included previous medical and ocular history, previous and subsequent ranibizumab injections administered for DME, visual acuity (VA), central macular thickness throughout the follow-up period, and the occurrence of any complications. Read More

    Efficiency and safety of laser photocoagulation with or without intravitreal ranibizumab for treatment of diabetic macular edema: a systematic review and Meta-analysis.
    Int J Ophthalmol 2017 18;10(7):1134-1143. Epub 2017 Jul 18.
    Department of Ophthalmology, Shanghai General Hospital; Shanghai Key Laboratory of Ocular Fundus Diseases, Shanghai 200080, China.
    Aim: To compare the therapeutic effect and safety of laser photocoagulation along with intravitreal ranibizumab (IVR) versus laser therapy in treatment of diabetic macular edema (DME).

    Methods: Pertinent publications were identified through comprehensive searches of PubMed, EMBASE, Web of Science, Cochrane Library, and ClinicalTrials.gov to identify randomized clinical trials (RCTs) comparing IVR+laser to laser monotherapy in patients with DME. Read More

    Diabetic macular edema in proliferative stage treated with anti-vascular endothelial growth factor agent and triamcinolone acetonide by laser-based strategies.
    Int J Ophthalmol 2017 18;10(7):1113-1119. Epub 2017 Jul 18.
    Department of Ophthalmology, Guangdong General Hospital Affiliated to Southern Medical University, Guangzhou 510515, Guangdong Province, China.
    Aim: To appraise the effect of treatment for diabetic macular edema (DME) in proliferative stage with sufficient panrentinal photocoagulation (PRP) therapy and intravitreal injections (IV) Conbercept and posterior subtenon's triamcinolone acetonide (STTA) sequential therapy.

    Methods: This prospective clinical randomized controlled trial of cross-over design was conducted in three phases. The participants included cases of DME in proliferative stage. Read More

    Frequency of diabetic retinopathy and associated risk factors in Khartoum, Sudan: population based study.
    Int J Ophthalmol 2017 18;10(6):948-954. Epub 2017 Jun 18.
    Department of Medicine and HIV Metabolic Clinic, Milton Keynes University Hospital NHS Foundation Trust, Eaglestone, Milton Keynes, Buckinghamshire MK 6 5LD, UK.
    Aim: To assess the frequency and associated risk factors of diabetic retinopathy among Sudanese individuals with diabetes attending Makka Eye complex in Khartoum, Sudan.

    Methods: The cross sectional hospital based study recruited 316 individuals with diabetes from Makkah Eye Complex Retina Clinic. Standard questionnaire was used to collect demographic data, medical history and life style characteristics. Read More

    Structural Changes of the Macula on Optical Coherence Tomography after Vitrectomy for Proliferative Diabetic Retinopathy.
    Ophthalmologica 2017 Jul 21. Epub 2017 Jul 21.
    Department of Ophthalmology, Samsung Changwon Hospital, Sungkyunkwan University, Changwon, South Korea.
    Purpose: This study aimed to evaluate the relationship between macular structural changes and visual prognosis after pars plana vitrectomy (PPV) for proliferative diabetic retinopathy.

    Methods: The study included 60 eyes that had undergone PPV. Macular optical coherence tomography (OCT) findings were classified into 5 groups preoperatively and 10 groups postoperatively. Read More

    Drug-resistant coagulase-negative staphylococcal endophthalmitis following dexamethasone intravitreal implant.
    Indian J Ophthalmol 2017 Jul;65(7):634-636
    Sankara Eye Centre, Coimbatore, Tamil Nadu, India.
    A 60-year-old female came to our hospital with defective vision due to persistent diabetic macular edema and was treated with intravitreal ozurdex implant in the right eye. Three days later, the patient presented with diminution of vision, ocular pain, congestion, and hypopyon with no fundus view. B-scan ultrasonography showed vitritis, and diagnosis of endophthalmitis was made. Read More

    Real-world evidence of safety profile of intravitreal bevacizumab (Avastin) in an Indian scenario.
    Indian J Ophthalmol 2017 Jul;65(7):596-602
    Department of Vitreoretina, Giridhar Eye Institute, Kochi, Kerala, India.
    Purpose: The purpose of this study was to evaluate the safety profile of intravitreal bevacizumab (Avastin) as an off-label pharmacotherapeutic agent for various ocular conditions.

    Methods: Retrospective analysis was carried out on 3806 injections of 1761 patients that were administered with intravitreal bevacizumab injection at a tertiary eye care center in India. The injections were administered on a pro re nata basis for various indications such as age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO). Read More

    Diabetic retinopathy: current understanding, mechanisms, and treatment strategies.
    JCI Insight 2017 Jul 20;2(14). Epub 2017 Jul 20.
    Centre for Experimental Medicine, Queen's University Belfast, Northern Ireland, United Kingdom.
    Diabetic retinopathy (DR) causes significant visual loss on a global scale. Treatments for the vision-threatening complications of diabetic macular edema (DME) and proliferative diabetic retinopathy (PDR) have greatly improved over the past decade. However, additional therapeutic options are needed that take into account pathology associated with vascular, glial, and neuronal components of the diabetic retina. Read More

    Therapeutic Targeting Tumor Progression Locus-2 (TPL2)/Activating Transcription Factor-4 (ATF4)/Chemokine Stromal Cell-Derived Factor-α (SDF1α) Axis Suppresses Diabetic Retinopathy.
    Circ Res 2017 Jul 19. Epub 2017 Jul 19.
    Institute of Biomedical Sciences, National Chung Hsing University
    Rationale: Diabetic retinopathy is characterized by vasopermeability, vascular leakage, inflammation, blood-retinal barrier breakdown, capillary degeneration and neovascularization. However, the mechanisms underlying the association between diabetes and progression retinopathy remain unclear. Objective: Tumor progression locus 2 (TPL2), a serine-threonine protein kinase, exerts a pathological effect on vascular angiogenesis. Read More

    Is leukostasis a crucial step or epiphenomenon in the pathogenesis of diabetic retinopathy?
    J Leukoc Biol 2017 Jul 19. Epub 2017 Jul 19.
    Department of Ophthalmology, Ocular Angiogenesis Group, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands;
    Leukostasis in the retinal microvasculature in animal model studies of diabetes is associated with the development of diabetes-like retinopathy. Therefore, it is generally assumed that adhesion of leukocytes is a central event inciting a chronic, low-grade form of inflammation that causes the vascular abnormalities that are specific for the early stages of diabetic retinopathy (DR), which culminate in diabetic macular edema, proliferative DR, and vision loss in humans. Here, we review the literature critically with respect to leukostasis and assess its pathologic consequences in the human diabetic retina. Read More

    Inhibition of Single Routes of Intracellular Signaling is Not Sufficient to Neutralize the Biphasic Disturbance of a Retinal Endothelial Cell Barrier Induced by VEGF-A165.
    Cell Physiol Biochem 2017 Jul 18;42(4):1493-1513. Epub 2017 Jul 18.
    Background/aims: Hallmark of diabetic macular edema is the enhanced permeability of retinal endothelial cells (REC) induced by vascular endothelial growth factor (VEGF-A165), which acts through activating specific receptors. To improve the predictability of inhibitors' potentials to block harmful effects of VEGF-A165, we investigated if its signaling pathways triggered in REC are redundant.

    Methods: Immortalized bovine REC monolayers were treated with inhibitors specific for various protein kinases in combination with VEGF-A165. Read More

    Setting Priorities for Diabetic Retinopathy Clinical Research and Identifying Evidence Gaps.
    Ophthalmol Retina 2017 Mar-Apr;1(2):94-102
    Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
    Purpose: Prioritizing comparative effectiveness research may contribute to obtaining answers that clinicians perceive they need and may minimize research that could be considered wasteful. Our objective was to identify evidence gaps and set priorities for new systematic reviews and randomized controlled trials for managing diabetic retinopathy (DR), including diabetic macular edema (DME).

    Design: Cross-sectional study. Read More

    Early Response to Ranibizumab Is Associated with 12-Month Outcome in Diabetic Macular Edema after Prior Macular Laser Therapy.
    Ophthalmologica 2017 Jul 18. Epub 2017 Jul 18.
    Department of Ophthalmology, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan.
    Purpose: To evaluate the efficacy of ranibizumab in persistent or recurrent diabetic macular edema (DME) after previous laser therapy.

    Methods: This prospective, interventional study consisted of a 3-month period of scheduled ranibizumab treatment followed by a 9-month period of pro re nata treatment.

    Results: A total of 21 eyes (18 patients) were included. Read More

    TNFα-Induced Disruption of the Blood-Retinal Barrier In Vitro Is Regulated by Intracellular 3',5'-Cyclic Adenosine Monophosphate Levels.
    Invest Ophthalmol Vis Sci 2017 Jul;58(9):3496-3505
    Ocular Angiogenesis Group, Departments of Ophthalmology and Medical Biology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
    Purpose: Proinflammatory cytokines such as tumor necrosis factor (TNFα) may have a causative role in blood-retinal barrier (BRB) disruption, which is an essential step in the development of diabetic macular edema. The purpose of our study was to determine whether TNFα increases permeability in an in vitro model of the BRB and to explore the mechanisms involved.

    Methods: Primary bovine retinal endothelial cells (BRECs) were grown on Transwell inserts and cells were stimulated with TNFα or a combination of TNFα, IL1β, and VEGF. Read More

    Rapid response to dexamethasone intravitreal implant in diabetic macular edema.
    Eur J Ophthalmol 2017 Jul 1. Epub 2017 Jul 1.
    San Paolo Ophthalmic Center, San Antonio Hospital, Padua - Italy.
    Purpose: To evaluate the early effects of dexamethasone (DEX) intravitreal implants in patients with diabetic macular edema (DME).

    Methods: This was a prospective, single-arm, interventional clinical series. Eighteen patients (18 eyes) with chronic/recalcitrant or naive DME were included. Read More

    Dexamethasone Implants in Diabetic Macular Edema Patients with High Visual Acuity.
    Ophthalmic Res 2017 Jul 14. Epub 2017 Jul 14.
    Eye Clinic, Department of Neurological, Biomedical, and Movement Sciences, University of Verona, Verona, Italy.
    Purpose: To evaluate the effects of intravitreal dexamethasone (DEX) implants in patients affected by diabetic macular edema (DME) with high best-corrected visual acuity (BCVA) and contraindications to therapy with anti-vascular endothelial growth factor over a 12-month follow-up.

    Methods: In this interventional nonrandomized clinical study, 14 consecutive patients (14 eyes) affected by DME with a BCVA of 0.3 LogMAR or better were prospectively enrolled. Read More

    Nicotine promotes blood retinal barrier damage in a model of human diabetic macular edema.
    Toxicol In Vitro 2017 Jul 6. Epub 2017 Jul 6.
    Section of Human Anatomy and Histology, Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy. Electronic address:
    More than 1 billion world's population actively smokes tobacco containing the bioactive component nicotine (NT). The biological role of this molecule is mediated through the activation of nicotinic cholinergic receptors, widely distributed in various human tissues including retinal pigmented epithelium. The long-term assumption of NT contributes to several diseases development such as diabetic retinopathy. Read More

    Ultra-wide-field imaging in diabetic retinopathy.
    Vision Res 2017 Jul 5. Epub 2017 Jul 5.
    Department of Ophthalmology, David Geffen School of Medicine at UCLA, Los Angeles, California, USA; Doheny Eye Institute, Los Angeles, California, USA. Electronic address:
    Since 1991, 7-field images captured with 30-50 degree cameras in the Early Treatment Diabetic Retinopathy Study were the gold standard for fundus imaging to study diabetic retinopathy. Ultra-wide-field images cover significantly more area (up to 82%) of the fundus and with ocular steering can in many cases image 100% of the fundus ("panretinal"). Recent advances in image analysis of ultra-wide-field imaging allow for precise measurements of the peripheral retinal lesions. Read More

    Diabetic macular edema with and without subfoveal neuroretinal detachment: two different morphological and functional entities.
    Am J Ophthalmol 2017 Jul 4. Epub 2017 Jul 4.
    Department of Ophthalmology, University of Padova, Italy; Fondazione G. B. Bietti, IRCCS, Roma, Italy. Electronic address:
    Purpose: To assess specific morphologic and functional characteristics in eyes with diabetic macular edema (DME) with subfoveal neuroretinal detachment (SND+) vs DME without SND (SND-).

    Design: Cross-sectional, prospective, comparative case series.

    Methods: Seventy two patients (72 eyes: 22 eyes SND+ and 50 eyes SND-) with treatment-naïve, center-involving DME were evaluated. Read More

    Are we making good use of our public resources? The false-positive rate of screening by fundus photography for diabetic macular oedema.
    Hong Kong Med J 2017 Jul 7. Epub 2017 Jul 7.
    Department of Ophthalmology, The University of Hong Kong, Pokfulam, Hong Kong.
    Introduction: A large proportion of patients diagnosed with diabetic maculopathy using fundus photography and hence referred to specialist clinics following the current screening guidelines adopted in Hong Kong and United Kingdom are found to be false-positive, implying that they did not have macular oedema. This study aimed to evaluate the false-positive rate of diabetic maculopathy screening using the objective optical coherence tomography scan.

    Methods: This was a cross-sectional observational study. Read More

    Binocular Fixation Reduces Fixational Eye Movements in the Worst Eye of Patients with Center-Involving Diabetic Macular Edema.
    Ophthalmic Res 2017 Jul 7. Epub 2017 Jul 7.
    Department of Ophthalmology, Aarhus University Hospital, Aarhus, Denmark.
    Purpose: Treatment of diabetic maculopathy with vascular endothelial growth factor inhibitors is in some patients ineffective, and, therefore, parameters predicting visual outcome after treatment should be identified. It has been shown that fixational saccades are increased in patients with reduced visual acuity secondary to diabetic maculopathy, but it is unknown to what extent these saccades in an eye affected by diabetic maculopathy are influenced by the other eye during binocular fixation.

    Methods: In 57 eyes from 29 diabetic patients with clinically significant macular edema, fixational eye movements were recorded using the iView X™ video-based eye tracker, and quantitative measures of fixation with the worst eye obtained during monocular and binocular fixation were compared. Read More

    Ocriplasmin treatment for vitreomacular traction in real life: can the indication spectrum be expanded?
    Graefes Arch Clin Exp Ophthalmol 2017 Jul 5. Epub 2017 Jul 5.
    Ophthalmology Department, State Hospital Feldkirch, Academic Teaching Hospital, Carinagasse 47, 6800, Feldkirch, Austria.
    Purpose: To evaluate the efficacy of intravitreal ocriplasmin for the resolution of vitreomacular traction (VMT) with or without a full thickness macular hole (FTMH) in the clinical setting and to assess whether the indication spectrum of this treatment modality can be expanded beyond that of the MIVI-TRUST trials.

    Methods: The records of patients with VMT with or without FTMH, who were treated with intravitreal ocriplasmin were reviewed. Patients were divided in two groups. Read More

    Pro- and antiangiogenic VEGF and its receptor status for the severity of diabetic retinopathy.
    Mol Vis 2017 22;23:356-363. Epub 2017 Jun 22.
    Regional Medical Research Centre-NE Region (Indian Council of Medical Research), Assam, India.
    Purpose: Alteration of pro- and antiangiogenic homeostasis of vascular endothelial growth factor (VEGF) isoforms in patients with hyperglycemia seems crucial but substantially unexplored at least quantitatively for diabetic retinopathy (DR). Therefore, in the present study we aimed to estimate the difference between the pro- (VEGF165a) and antiangiogenic (VEGF165b) VEGF isoforms and its soluble receptors for severity of DR.

    Methods: The study included 123 participants (diabetic retinopathy: 81, diabetic control: 20, non-diabetic control: 22) from the Regional Institute of Ophthalmology, Kolkata. Read More

    Evaluating the impact of optical coherence tomography in diabetic retinopathy screening for an Aboriginal population.
    Clin Exp Ophthalmol 2017 Jul 4. Epub 2017 Jul 4.
    Lions Outback Vision, Perth, Australia.
    Importance: Optical Coherence Tomography (OCT) is used routinely in management of diabetic eye disease but has not been evaluated in Australian outreach settings for screening programs.

    Background: To evaluate the use of OCT combined with a fundus camera compared to a fundus camera only in a telehealth diabetic retinopathy (DR) screening program for Aboriginal Australians.

    Design: Retrospective comparative study. Read More

    Evaluation of pain during intravitreal aflibercept injections.
    Eur J Ophthalmol 2017 Jun 20. Epub 2017 Jun 20.
    Department of Ophthalmology, Ulucanlar Eye Training and Research Hospital, Ankara - Turkey.
    Purpose: To evaluate the pain associated with intravitreal aflibercept injections.

    Methods: The study included 119 patients who received intravitreal aflibercept injection at a single institution. Pain was evaluated by visual analog scale (VAS) immediately after the injection of 2 mg/0. Read More

    Vascular Adhesion Protein-1 Blockade Suppresses Ocular Inflammation After Retinal Laser Photocoagulation in Mice.
    Invest Ophthalmol Vis Sci 2017 Jun;58(7):3254-3261
    Laboratory of Ocular Cell Biology & Visual Science, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan 2Department of Ophthalmology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
    Purpose: To investigate the effect of the vascular adhesion protein-1 (VAP-1) inhibitor RTU-1096 on retinal morphologic changes and ocular inflammation after retinal laser photocoagulation in mice.

    Methods: C57BL/6JJcl mice were fed a diet containing RTU-1096, a specific inhibitor for VAP-1, or a control diet ad libitum for 7 days. Laser photocoagulation was performed on the peripheral retina of the animals. Read More

    Combined poor diabetes control indicators are associated with higher risks of diabetic retinopathy and macular edema than poor glycemic control alone.
    PLoS One 2017 29;12(6):e0180252. Epub 2017 Jun 29.
    Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, University of Melbourne, Melbourne, Australia.
    Purpose: To examine the association of individual and combined indicators of diabetes control with diabetic retinopathy and diabetic macular edema.

    Materials And Methods: In this clinical, cross-sectional study, 613 adults with type 2 diabetes (372 any diabetic retinopathy; 183 any diabetic macular edema) were examined. Diabetic retinopathy was assessed from fundus photographs; diabetic macular edema from Ocular Coherence Tomography scans; and HbA1c and serum lipid values from fasting blood samples. Read More

    Effect of intravitreal ranibizumab on the ocular circulation of the untreated fellow eye.
    Graefes Arch Clin Exp Ophthalmol 2017 Jun 28. Epub 2017 Jun 28.
    Department of Ophthalmology, Mie University Graduate School of Medicine, 2-175 Edobashi, Tsu, 514-8507, Japan.
    Purpose: To evaluate the effects of unilateral intravitreal ranibizumab (IVR) on the ocular circulation of the fellow eyes.

    Methods: Fifteen eyes of 15 patients with macular edema (average age 69.6 ± 11. Read More

    Erythropoietin in diabetic retinopathy.
    Vision Res 2017 Jun 23. Epub 2017 Jun 23.
    Ophthalmology Department, Belfast Health and Social Care Trust, Royal Victoria Hospital, 274 Grosvenor Rd, Belfast BT12 6BA; Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, 97 Lisburn Road, BT9 7BL Belfast, UK. Electronic address:
    Over the past years, knowledge has expanded with regards to the multiple roles played by Erythropoietin (EPO) in the body. Once believed to be a hormone synthesised in the kidney and involved only in the modulation of erythrocyte production, it is recognised now that EPO can be produced in many tissues, including the retina, and by many cells. In these tissues EPO is released in response to "tissue injury" and appears to have protective functions. Read More

    Comparison of vitrectomized with nonvitrectomized eyes after subtenon injection of triamcinolone acetonide to treat diabetic macular edema: Retrospective comparative Analysis of an interventional case series.
    Indian J Ophthalmol 2017 Jun;65(6):488-492
    Department of Ophthalmology, School of Medicine, Pusan National University; Biomedical Research Institute, Pusan National University Hospital, Busan, South Korea.
    Purpose: Triamcinolone acetonide (TA) is an alternative option for diabetic macular edema thanks to its cost-benefit ratio and unique delivery route. We performed this study to compare vitrectomized with nonvitrectomized eyes treated with subtenon TA injection for diabetic macular edema.

    Materials And Methods: We retrospectively reviewed the medical records of patients who had undergone subtenon TA injection for diabetic macular edema treatment. Read More

    Visualization of changes in the foveal avascular zone in both observed and treated diabetic macular edema using optical coherence tomography angiography.
    Int J Retina Vitreous 2017 19;3:19. Epub 2017 Jun 19.
    New England Eye Center, Tufts Medical Center, Tufts University, 800 Washington Street, Box 450, Boston, MA 02111 USA.
    Background: Central vision loss in diabetic retinopathy is commonly related to diabetic macular edema (DME). The objective of this study was to describe changes between consecutive visits on optical coherence tomography angiography (OCTA) of the foveal avascular zone (FAZ) in eyes with DME.

    Methods: 20 eyes from 14 patients with DME were imaged on 2 successive clinic visits separated by at least 1 month. Read More

    Corticosteroid Treatment in Diabetic Macular Edema.
    Turk J Ophthalmol 2017 Jun 1;47(3):156-160. Epub 2017 Jun 1.
    Ankara Training and Research Hospital, Ophthalmology Clinic, Ankara, Turkey.
    Diabetic macular edema is the most common cause of visual impairment in patients with diabetes mellitus. The pathogenesis of macular edema is complex and multifactorial. For many years, laser photocoagulation has been considered the standard therapy for the treatment of diabetic macular edema; however, few patients achieve significant improvements in visual acuity. Read More

    Triamcinolone Acetonide Suppresses Inflammation and Facilitates Vascular Barrier Function in Human Retinal Microvascular Endothelial Cells.
    Curr Neurovasc Res 2017 Jun 18. Epub 2017 Jun 18.
    Molecular Pharmacology, Department of Biofunctional Evaluation, Gifu Pharmaceutical University, Gifu. Japan.
    Background: Diabetic macular edema (DME) is resulted from the retinal microvascular leakage that accompanies the breakdown of blood-retinal barrier. Triamcinolone acetonide (TA) is a therapeutic agent for DME, but since the detailed mechanism of action of TA is not known, part of its action was examined.

    Methods: In vitro model to enhance the permeability of human retinal microvascular endothelial cells (HRMECs) was constructed by using DME-related cytokines such as vascular endothelial growth factor (VEGF), tumor necrosis factor-α (TNF-α), and interleukin-1β (IL-1β). Read More

    Identification of time point to best define 'sub-optimal response' following intravitreal ranibizumab therapy for diabetic macular edema based on real-life data.
    Eye (Lond) 2017 Jun 16. Epub 2017 Jun 16.
    National Institute for Health Research, Biomedical Research Centre at Moorfields Eye Hospital National Health Service Foundation Trust and UCL Institute of Ophthalmology, London, UK.
    PurposeTo determine the average time-point at which it is best to define 'sub-optimal response' after ranibizumab treatment for diabetic macular edema (DME) based on the data obtained from real-life clinical practice.MethodsIn this retrospective observational study, 322 consecutive treatment naïve eyes with DME were treated with three loading doses of intravitreal ranibizumab followed by re-treatment based on decision of the treating physician on a case-by-case basis. The demographic data, clinic-based visual acuity measurements and central subfield thickness (CST) assessed on spectral domain optical coherence tomography (OCT) were evaluated at baseline (month 0), 1, 2, 3, 6, and 12 months. Read More

    Effects of intravitreal injection of bevacizumab with or without anterior chamber paracentesis on intraocular pressure and peripapillary retinal nerve fiber layer thickness: a prospective study.
    Graefes Arch Clin Exp Ophthalmol 2017 Jun 14. Epub 2017 Jun 14.
    Ophthtalmic Research Center, Shahid Beheshti University of Medical Sciences, Labbafinejad Medical Center, Tehran, Iran.
    Purpose: To investigate the effects of intravitreal injection of bevacizumab (IVB) with or without anterior chamber paracentesis on intraocular pressure (IOP) and peripapillary retinal nerve fiber layer (PRNFL) thickness.

    Methods: In this prospective randomized clinical trial, 90 eyes with center involving diabetic macular edema or wet type age-related macular degeneration (AMD) were randomly assigned to receive IVB either without (group A) or with (group B) anterior chamber paracentesis. IOP was measured before and within 2 min, 30 min, 24 hours and 3 months after injections. Read More

    OPTICAL COHERENCE TOMOGRAPHY BASELINE PREDICTORS FOR INITIAL BEST-CORRECTED VISUAL ACUITY RESPONSE TO INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT IN EYES WITH DIABETIC MACULAR EDEMA: The CHARTRES Study.
    Retina 2017 May 2. Epub 2017 May 2.
    *AIBILI, Association for Innovation and Biomedical Research on Light and Image Coimbra, Portugal; Orthoptics Scientific Area,†School of Allied Health Technologies, Polytechnic Institute of Porto, Porto, Portugal;‡Department of Ophthalmology, Coimbra University Hospital Center, Coimbra, Portugal; and§Faculty of Medicine, University of Coimbra, Coimbra, Portugal.
    Purpose: To identify baseline optical coherence tomography morphologic characteristics predicting the visual response to anti-vascular endothelial growth factor therapy in diabetic macular edema.

    Methods: Sixty-seven patients with diabetic macular edema completed a prospective, observational study (NCT01947881-CHARTRES). All patients received monthly intravitreal injections of Lucentis for 3 months followed by PRN treatment and underwent best-corrected visual acuity measurements and spectral domain optical coherence tomography at Baseline, Months 1, 2, 3, and 6. Read More

    MACULAR EDEMA AFTER CATARACT SURGERY IN EYES WITH PREOPERATIVE RETINAL VEIN OCCLUSION.
    Retina 2017 May 2. Epub 2017 May 2.
    Department of Ophthalmology, Kim's Eye Hospital, Myung-Gok Eye Research Institute, Konyang University College of Medicine, Seoul, South Korea.
    Purpose: To evaluate the incidence of pseudophakic macular edema (PME) in eyes with a history of retinal vein occlusion before cataract surgery and to identify any associated risk factors.

    Methods: The records of 21,332 eyes that underwent cataract surgery were retrospectively reviewed. Eyes that had retinal vein occlusion preoperatively with no evidence of macular pathology on optical coherence tomography at the time of surgery and no macular edema treatment at least 6 months before surgery were included. Read More

    A Case of Diabetic Macular Edema with Prominent Chorioretinal Folds.
    Case Rep Ophthalmol 2017 Jan-Apr;8(1):163-169. Epub 2017 Mar 7.
    aDepartment of Ophthalmology, Osaka Medical College, Takatsuki, Japan.
    Purpose: To report a case of diabetic macular edema with prominent chorioretinal folds.

    Case Report: This study involved a 55-year-old male with untreated bilateral diabetic retinopathy who had undergone cataract surgery at another clinic. Following that surgery, diabetic macular edema rapidly exacerbated, accentuating marked cystoid macular edema and radial chorioretinal folds in the macula. Read More

    Efficacy of nepafenac ophthalmic suspension 0.1% in improving clinical outcomes following cataract surgery in patients with diabetes: an analysis of two randomized studies.
    Clin Ophthalmol 2017 29;11:1021-1029. Epub 2017 May 29.
    Lehmann Eye Center, Nacogdoches, TX, USA.
    Objective: To assess the efficacy of nepafenac 0.1% ophthalmic suspension in improving the clinical outcomes following cataract surgery (CS) in patients with nonproliferative diabetic retinopathy.

    Methods: In two similar multicenter, randomized studies, patients received either nepafenac 0. Read More

    Connexin channel and its role in diabetic retinopathy.
    Prog Retin Eye Res 2017 Jun 8. Epub 2017 Jun 8.
    Departments of Medicine and Ophthalmology, Boston University School of Medicine, Boston, MA, United States.
    Diabetic retinopathy is the leading cause of blindness in the working age population. Unfortunately, there is no cure for this devastating ocular complication. The early stage of diabetic retinopathy is characterized by the loss of various cell types in the retina, namely endothelial cells and pericytes. Read More

    VEGF production and signaling in Müller glia are critical to modulating vascular function and neuronal integrity in diabetic retinopathy and hypoxic retinal vascular diseases.
    Vision Res 2017 Jun 21. Epub 2017 Jun 21.
    Departments of Medicine Endocrinology, Cell Biology, and Ophthalmology, and Harold Hamm Diabetes Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA. Electronic address:
    Müller glia (MG) are major retinal supporting cells that participate in retinal metabolism, function, maintenance, and protection. During the pathogenesis of diabetic retinopathy (DR), a neurovascular disease and a leading cause of blindness, MG modulate vascular function and neuronal integrity by regulating the production of angiogenic and trophic factors. In this article, I will (1) briefly summarize our work on delineating the role and mechanism of MG-modulated vascular function through the production of vascular endothelial growth factor (VEGF) and on investigating VEGF signaling-mediated MG viability and neural protection in diabetic animal models, (2) explore the relationship among VEGF and neurotrophins in protecting Müller cells in in vitro models of diabetes and hypoxia and its potential implication to neuroprotection in DR and hypoxic retinal diseases, and (3) discuss the relevance of our work to the effectiveness and safety of long-term anti-VEGF therapies, a widely used strategy to combat DR, diabetic macular edema, neovascular age-related macular degeneration, retinopathy of prematurity, and other hypoxic retinal vascular disorders. Read More

    Localization of optic disc and fovea in retinal images using intensity based line scanning analysis.
    Comput Biol Med 2017 Apr 27. Epub 2017 Apr 27.
    Department of Electrical and Electronic Engineering, Center for Intelligent Signal and Imaging Research (CISIR), Universiti Teknologi Petronas, Tronoh, 32610 Seri Iskandar, Perak, Malaysia.
    Accurate detection of diabetic retinopathy (DR) mainly depends on identification of retinal landmarks such as optic disc and fovea. Present methods suffer from challenges like less accuracy and high computational complexity. To address this issue, this paper presents a novel approach for fast and accurate localization of optic disc (OD) and fovea using one-dimensional scanned intensity profile analysis. Read More

    Machine learning techniques for diabetic macular edema (DME) classification on SD-OCT images.
    Biomed Eng Online 2017 Jun 7;16(1):68. Epub 2017 Jun 7.
    LE2I, CNRS, Arts et Métiers, Université Bourgogne Franche-Comté, 12 rue de la Fonderie, Le Creusot, France.
    Background: Spectral domain optical coherence tomography (OCT) (SD-OCT) is most widely imaging equipment used in ophthalmology to detect diabetic macular edema (DME). Indeed, it offers an accurate visualization of the morphology of the retina as well as the retina layers.

    Methods: The dataset used in this study has been acquired by the Singapore Eye Research Institute (SERI), using CIRRUS TM (Carl Zeiss Meditec, Inc. Read More

    Distribution of Nonperfusion Area on Ultra-widefield Fluorescein Angiography in Eyes With Diabetic Macular Edema: DAVE Study.
    Am J Ophthalmol 2017 Jun 1. Epub 2017 Jun 1.
    Doheny Image Reading Center, Doheny Eye Institute, Los Angeles, California; Department of Ophthalmology, David Geffen School of Medicine at UCLA, Los Angeles, California. Electronic address:
    Purpose: To explore the distribution of nonperfusion area (NPA) in eyes with diabetic macular edema (DME) and its relationship with the severity of DME.

    Design: Prospective, observational case series.

    Methods: Forty eyes of 29 patients with treatment-naïve DME who participated in the DAVE study (NCT01552408) were included. Read More

    Ischemic index changes in diabetic retinopathy after intravitreal dexamethasone implant using ultra-widefield fluorescein angiography: a pilot study.
    Acta Diabetol 2017 Aug 2;54(8):769-773. Epub 2017 Jun 2.
    Department of Ophthalmology, University Vita-Salute, IRCCS Ospedale San Raffaele, Via Olgettina 60, Milan, 20132, Italy.
    Aims: To investigate the effect of dexamethasone intravitreal implant on peripheral ischemia in patients affected by diabetic macular edema (DME).

    Methods: Patients with treatment-naïve diabetic retinopathy (DR) undergoing intravitreal dexamethasone implant for DME between October 2015 and March 2017 were enrolled. Patients underwent a comprehensive ocular examination at baseline (<2 weeks before treatment) and 10 ± 2 weeks after dexamethasone implant including best-corrected visual acuity (BCVA), intraocular pressure, optical coherence tomography, ultra-widefield (UWF) retinography and UWF fluorescein angiography (UWFA). Read More

    Qualitative and Quantitative Assessment of Vascular Changes in Diabetic Macular Edema after Dexamethasone Implant Using Optical Coherence Tomography Angiography.
    Int J Mol Sci 2017 Jun 2;18(6). Epub 2017 Jun 2.
    Ophthalmology Clinic, Department of Medicine and Science of Ageing, University "G. D'Annunzio" Chieti-Pescara, Chieti 66100, Italy.
    The aim of this study was to investigate retinal and choriocapillaris vessel changes in diabetic macular edema (DME) after the intravitreal dexamethasone implant (IDI) using optical coherence tomography angiography (OCTA). Moreover, a comparison between morphological and functional parameters of DME and healthy patients was performed. Twenty-five eyes of 25 type 2 diabetic retinopathy patients complicated by macular edema (DME group) and 25 healthy subjects (control group) were enrolled. Read More

    Pars Plana Vitrectomy with Internal Limiting Membrane Peeling for Nontractional Diabetic Macular Edema.
    Open Ophthalmol J 2017 31;11:5-10. Epub 2017 Jan 31.
    Department of Ophthalmology, University of North Carolina at Chapel Hill, United States.
    Background: Diabetes mellitus remains the leading cause of blindness among working age Americans with diabetic macular edema being the most common cause for moderate and severe vision loss.

    Objective: To investigate the anatomical and visual benefits of pars plana vitrectomy with inner limiting membrane peeling in patients with nontractional diabetic macular edema as well as correlation of integrity of outer retinal layers on spectral domain optical coherence tomography to visual outcomes.

    Methods: We retrospectively reviewed the charts of 42 diabetic patients that underwent vitrectomy with internal limiting membrane peeling for nontractional diabetic macula edema. Read More

    1 OF 84